A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo
MK Verma, J Clemens, L Burzenski… - Journal of …, 2017 - Elsevier
Monoclonal antibodies (mAbs) have emerged as a mainstream therapeutic option against
cancer. mAbs mediate tumor cell-killing through several mechanisms including complement-
dependent cytotoxicity (CDC). However, studies of mAb-mediated CDC against tumor cells
remain largely dependent on in vitro systems. Previously developed and widely used NOD-
scid IL2rγ null (NSG) mice support enhanced engraftment of many primary human tumors.
However, NSG mice have a 2-bp deletion in the coding region of the hemolytic complement …
cancer. mAbs mediate tumor cell-killing through several mechanisms including complement-
dependent cytotoxicity (CDC). However, studies of mAb-mediated CDC against tumor cells
remain largely dependent on in vitro systems. Previously developed and widely used NOD-
scid IL2rγ null (NSG) mice support enhanced engraftment of many primary human tumors.
However, NSG mice have a 2-bp deletion in the coding region of the hemolytic complement …
